Beresford Discusses Using VeriStrat With Immunotherapies

Paul Beresford, PhD
Published: Tuesday, May 12, 2015



Paul Beresford, PhD, Biodesix, discusses utilizing VeriStrat technology to select which patients may benefit from immunotherapies.

VeriStrat is a serum proteomic test that helps physicians select treatment. It is primarily marketed for use in advanced non-small cell lung cancer patients; however, it can be applied to multiple tumor types, said Beresford.

Early stage feasibility studies show that the VeriStrat platform may be able to identify which patients will benefit from immunotherapies, including checkpoint inhibitors.

Biodesix is also involved in generating new classifiers through their proteomic platform, which is uniquely suited to addressing questions regarding the impact of immunotherapies on the tumor, says Beresford.

SELECTED
LANGUAGE


Paul Beresford, PhD, Biodesix, discusses utilizing VeriStrat technology to select which patients may benefit from immunotherapies.

VeriStrat is a serum proteomic test that helps physicians select treatment. It is primarily marketed for use in advanced non-small cell lung cancer patients; however, it can be applied to multiple tumor types, said Beresford.

Early stage feasibility studies show that the VeriStrat platform may be able to identify which patients will benefit from immunotherapies, including checkpoint inhibitors.

Biodesix is also involved in generating new classifiers through their proteomic platform, which is uniquely suited to addressing questions regarding the impact of immunotherapies on the tumor, says Beresford.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Harnessing the Predictive Powers of Biomarkers in Immuno-OncologyJul 31, 20191.0
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x